Glowing dye could help surgeons remove sarcomas in one go
NCT ID NCT06409013
First seen Jun 26, 2026 · Last updated Aug 05, 2026 · Updated 3 times
Summary
This study tests whether a dye called indocyanine green can help surgeons see if any cancer remains after removing a sarcoma. About 50 adults with bone or soft tissue sarcoma will receive the dye during surgery, and the surgeon will check for glowing areas that might indicate leftover tumor. The goal is to see if this technique matches lab results and could reduce the need for follow-up surgeries.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- indocyanine green dye
- What this could lead to
- If it works, this could help surgeons remove sarcomas more completely in one operation, reducing the need for additional surgeries.
- What could go wrong
- This is a small, early study with only 50 participants. The dye may not always match lab results, and some people may have allergic reactions.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 75 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Mar 2024
- Expected to finish
-
Mar 2027
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Patients with biopsy-proven bone or soft tissue sarcoma undergoing resection recruited through Mayo Clinic
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Patients with biopsy-proven bone or soft tissue sarcoma undergoing resection Exclusion Criteria: * Chronic kidney disease * Anaphylaxis to dyes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bone sarcoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The study's own enquiry address
This study publishes an address for enquiries. See it below .
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a dual immune antibody plus radiation shrink metastatic sarcoma?
- Can a Marine-Derived drug slow advanced soft tissue sarcoma?
- Can a One-Two punch of immunotherapy and radiation tame sarcoma before surgery?
- Can a radioactive antibody light up hidden tumors?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Could a massive tissue bank unlock sarcoma's secrets?